CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF701 (ImmuneEditome ID:55762)

1. Gene summary of enriched editing regions for ZNF701

check button Gene summary
Gene informationGene symbol

ZNF701

Gene ID

55762

GeneSynonyms-
GeneCytomap

19q13.41

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 701
GeneModificationdate20230518
UniprotIDQ9NV72;M0R085;M0R327
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:52556155-52558680:+ENST00000478039.1ENSG00000167562.10ZNF701ncRNA_intronicAluSg,AluSq2,AluSx4,(T)n,AluSx,AluSp,AluYcchr19:52556155-52558680:+.alignment
chr19:52559752-52560325:+ENST00000478039.1ENSG00000167562.10ZNF701ncRNA_intronic(TAT)n,AluSx,AluSg4chr19:52559752-52560325:+.alignment
chr19:52586253-52586565:+ENST00000540331.1ENSG00000167562.10ZNF701UTR3AluYk11,AluJbchr19:52586253-52586565:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF701


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000167562.10,ZNF701COADEAG6.7298e-03image
chr19:52556155-52558680:+KICHEER3.7599e-02image
ENSG00000167562.10,ZNF701KICHEAG1.4944e-05image
chr19:52556155-52558680:+KIRPEER1.1593e-04image
chr19:52556155-52558680:+LUSCEER3.3219e-02image
ENSG00000167562.10,ZNF701LUSCEAG2.2653e-03image
ENSG00000167562.10,ZNF701STADEAG1.0660e-02image
chr19:52556155-52558680:+THCAEER5.2186e-03image
ENSG00000167562.10,ZNF701THCAEAG1.9395e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000167562.10,ZNF701THCAEAG2.6624e-021.0709e-026.6870e+07image

Top

3. Enriched editing regions and immune related genes for ZNF701


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52556155-52558680:+ESCAEERENSG00000198538,ZNF28-0.47676.2260e-055.6569e-08-0.4527imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52556155-52558680:+ESCAEERENSG00000198482,ZNF808-0.45951.2476e-045.8220e-10-0.5081imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52556155-52558680:+ESCAEERENSG00000182986,ZNF320-0.44672.3382e-043.0540e-07-0.4296imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52556155-52558680:+ESCAEERENSG00000204604,ZNF468-0.40111.2586e-031.1960e-06-0.4095imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52556155-52558680:+ESCAEERENSG00000006715,VPS41-0.39122.3010e-031.7210e-06-0.4039imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52556155-52558680:+ESCAEERENSG00000180257,ZNF816-0.38242.5284e-031.3766e-06-0.4073imageNADAR;ELAVL1;HNRNPMNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52556155-52558680:+ESCAEERENSG00000134590,FAM127A0.37413.9042e-031.5548e-080.4694imageNELAVL1;HNRNPMNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
chr19:52556155-52558680:+ESCAEERENSG00000175550,DRAP10.37154.2191e-039.1100e-080.4464imageNADAR;ELAVL1NAT_cells_CD4_memory_restingGSVA_HALLMARK_HYPOXIA
chr19:52556155-52558680:+ESCAEERENSG00000175573,C11orf680.33601.4418e-021.6824e-060.4042imageNELAVL1;HNRNPMNANK_cells_activatedGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:52556155-52558680:+ESCAEERENSG00000165886,UBTD10.32851.6164e-021.9837e-060.4017imageNADAR;ELAVL1;HNRNPMNAT_cells_CD4_memory_restingGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results



Top

4. Enriched editing regions and immune related splicing for ZNF701


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000167562.10,ZNF701
CESCEAGIRENSG00000176915.10chr12132734384:132734575:132734664:132735123-0.12572.8333e-026.2030e-09-0.4284imageNACIN1;ADAR;AUH;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGNAB_cells_memory
chr19:52556155-52558680:+
ESCAEERA5ENSG00000108946.10chr1768515393:68515536:68512899:68512970:68512899:685151190.41353.6260e-033.7772e-060.4016imageNELAVL1;HNRNPMPRKAR1AB_cells_naiveGSVA_HALLMARK_MYOGENESIS
ENSG00000167562.10,ZNF701
GBMEAGIRENSG00000188747.4chr9137433964:137434079:137434223:137434405-0.33337.1121e-039.2665e-06-0.4196imageNAUH;CPSF6;CSTF2T;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHDRBS1;LIN28B;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAGNOXA1NK_cells_restingGSVA_HALLMARK_ADIPOGENESIS
chr19:52556155-52558680:+
KICHEERIRENSG00000130349.5chr6107039748:107040230:107040380:107040462-0.57072.7829e-022.3290e-06-0.6120imageNADAR;ELAVL1;HNRNPMNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:52556155-52558680:+
OVEERA3ENSG00000105669.8chr1918904770:18904852:18903267:18903381:18903267:189033840.19539.8008e-032.9844e-090.4188imageNADAR;ELAVL1;HNRNPMNAT_cells_CD8
chr19:52556155-52558680:+
OVEERA3ENSG00000198755.6chr635468946:35469027:35469435:35469447:35469405:35469447-0.12552.7725e-026.8087e-11-0.4354imageNADAR;ELAVL1;HNRNPMNAGSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000167562.10,ZNF701
TGCTEAGIRENSG00000149016.11chr1162575044:62577291:62578560:625790300.33785.1832e-031.9983e-120.5308imageNAUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGNAMacrophages_M2GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000167562.10,ZNF701
TGCTEAGIRENSG00000066923.13chr7100200768:100201866:100201948:1002020150.33292.7789e-031.9059e-070.4317imageNACIN1;ADAR;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHSRP;LIN28B;LSM11;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SND1;SRSF1;SRSF10;TAF15;TARBP2;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000167562.10,ZNF701
TGCTEAGESENSG00000173559.8chr2191681945:191682017:191682491:191682595:191683728:1916838040.35183.7648e-041.2351e-080.4929imageNACIN1;ADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SBDS;SLTM;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGNAMast_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000167562.10,ZNF701
TGCTEAGESENSG00000160194.13chr2142896938:42897047:42903181:42904276:42908863:429091050.40603.0524e-044.3519e-090.4497imageNACIN1;ADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM22;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

5. Enriched editing regions and immune infiltration for ZNF701


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000167562.10,ZNF701ACCEAGMast_cells_resting8.9560e-040.4052image
chr19:52556155-52558680:+BLCAEERPlasma_cells2.4302e-020.1550image
ENSG00000167562.10,ZNF701BLCAEAGMacrophages_M25.9333e-030.1492image
chr19:52556155-52558680:+BRCAEERT_cells_regulatory_(Tregs)2.3173e-020.0804image
chr19:52586253-52586565:+BRCAEERMacrophages_M01.9029e-02-0.1219image
ENSG00000167562.10,ZNF701BRCAEAGDendritic_cells_activated5.8403e-030.0858image
chr19:52556155-52558680:+CESCEERT_cells_regulatory_(Tregs)3.3630e-020.1778image
chr19:52556155-52558680:+CHOLEERT_cells_regulatory_(Tregs)4.7102e-02-0.4489image
ENSG00000167562.10,ZNF701COADEAGB_cells_naive2.6592e-020.1498image
ENSG00000167562.10,ZNF701DLBCEAGMacrophages_M21.8687e-020.3798image
chr19:52556155-52558680:+ESCAEERT_cells_CD4_naive4.6662e-060.3880image
ENSG00000167562.10,ZNF701ESCAEAGMonocytes1.2038e-040.3193image
ENSG00000167562.10,ZNF701GBMEAGT_cells_regulatory_(Tregs)3.9068e-02-0.1798image
chr19:52556155-52558680:+HNSCEERT_cells_CD4_memory_activated2.1076e-020.2070image
ENSG00000167562.10,ZNF701HNSCEAGT_cells_CD4_memory_activated4.5849e-030.2002image
chr19:52556155-52558680:+KICHEERPlasma_cells1.3326e-030.4049image
chr19:52556155-52558680:+KIRCEERPlasma_cells4.3505e-030.1650image
chr19:52559752-52560325:+KIRCEERMacrophages_M01.5523e-030.3171image
ENSG00000167562.10,ZNF701KIRCEAGDendritic_cells_activated1.5365e-02-0.1264image
chr19:52556155-52558680:+KIRPEERB_cells_naive1.5927e-03-0.2363image
ENSG00000167562.10,ZNF701KIRPEAGMacrophages_M11.9770e-030.1885image
chr19:52556155-52558680:+LAMLEERDendritic_cells_activated2.4583e-020.1913image
chr19:52556155-52558680:+LGGEERT_cells_gamma_delta1.1708e-020.2524image
ENSG00000167562.10,ZNF701LGGEAGNK_cells_activated1.6826e-02-0.1222image
chr19:52556155-52558680:+LIHCEERMacrophages_M29.0141e-030.4029image
ENSG00000167562.10,ZNF701LIHCEAGMast_cells_resting6.7070e-030.2423image
chr19:52556155-52558680:+LUADEERDendritic_cells_activated2.1067e-020.1373image
ENSG00000167562.10,ZNF701LUADEAGT_cells_gamma_delta2.2553e-030.1497image
ENSG00000167562.10,ZNF701LUSCEAGDendritic_cells_resting3.4153e-02-0.1125image
ENSG00000167562.10,ZNF701MESOEAGMacrophages_M11.1553e-020.3024image
chr19:52556155-52558680:+OVEERMonocytes8.2754e-03-0.1809image
chr19:52586253-52586565:+OVEERMast_cells_activated3.3307e-03-0.2214image
ENSG00000167562.10,ZNF701OVEAGT_cells_CD81.0143e-030.1964image
chr19:52556155-52558680:+PAADEERNeutrophils4.0603e-020.2309image
ENSG00000167562.10,ZNF701PAADEAGB_cells_naive4.7991e-02-0.1602image
ENSG00000167562.10,ZNF701PCPGEAGB_cells_naive4.8431e-030.2151image
chr19:52556155-52558680:+PRADEERT_cells_CD4_naive6.5711e-030.1795image
ENSG00000167562.10,ZNF701PRADEAGMast_cells_resting4.0894e-020.0930image
chr19:52556155-52558680:+SARCEERNK_cells_resting3.9864e-02-0.2009image
ENSG00000167562.10,ZNF701SARCEAGNK_cells_resting4.0621e-02-0.1401image
chr19:52556155-52558680:+SKCMEERT_cells_follicular_helper2.9265e-02-0.1562image
ENSG00000167562.10,ZNF701SKCMEAGNK_cells_resting2.8991e-020.1219image
chr19:52556155-52558680:+STADEERT_cells_CD4_memory_activated6.9089e-030.1556image
chr19:52559752-52560325:+STADEERNK_cells_resting2.4584e-02-0.1519image
chr19:52586253-52586565:+STADEEREosinophils1.0402e-030.2577image
ENSG00000167562.10,ZNF701STADEAGT_cells_CD4_memory_activated7.0670e-040.1847image
chr19:52556155-52558680:+TGCTEERT_cells_CD4_memory_resting1.5279e-020.2248image
chr19:52586253-52586565:+TGCTEERMacrophages_M23.8985e-03-0.3030image
ENSG00000167562.10,ZNF701TGCTEAGT_cells_CD4_memory_resting4.5127e-070.3921image
chr19:52556155-52558680:+THCAEERMonocytes5.2615e-03-0.1351image
chr19:52559752-52560325:+THCAEERMast_cells_activated4.9347e-040.6681image
ENSG00000167562.10,ZNF701THCAEAGT_cells_CD4_memory_activated6.6082e-060.1996image
chr19:52556155-52558680:+THYMEERT_cells_CD4_memory_activated1.7672e-020.2733image
ENSG00000167562.10,ZNF701THYMEAGDendritic_cells_activated9.7778e-030.2390image
chr19:52556155-52558680:+UCECEERMacrophages_M02.3316e-020.2600image
ENSG00000167562.10,ZNF701UCECEAGDendritic_cells_activated1.8423e-020.1868image


Top

6. Enriched editing regions and immune gene sets for ZNF701


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000167562.10,ZNF701KIRPEAG3.4350e-02image2.3010e-040.2236image
ENSG00000167562.10,ZNF701STADEAG2.9908e-02image7.0765e-040.1847image
ENSG00000167562.10,ZNF701THCAEAG2.6770e-02image7.8492e-050.1753image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:52556155-52558680:+BLCAGSVA_HALLMARK_APICAL_SURFACEEER4.8586e-020.1359image
ENSG00000167562.10,ZNF701BLCAGSVA_HALLMARK_UV_RESPONSE_UPEAG6.4456e-030.1477image
chr19:52586253-52586565:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.3077e-050.2031image
chr19:52556155-52558680:+BRCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER5.2754e-030.0987image
ENSG00000167562.10,ZNF701BRCAGSVA_HALLMARK_HYPOXIAEAG4.5774e-060.1422image
ENSG00000167562.10,ZNF701CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7260e-020.1566image
ENSG00000167562.10,ZNF701CHOLGSVA_HALLMARK_UV_RESPONSE_DNEAG7.0147e-030.4672image
chr19:52556155-52558680:+CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.1949e-030.6112image
ENSG00000167562.10,ZNF701COADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0438e-040.2592image
chr19:52556155-52558680:+COADGSVA_HALLMARK_APICAL_SURFACEEER9.8151e-050.3870image
ENSG00000167562.10,ZNF701DLBCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG9.8131e-030.4138image
chr19:52556155-52558680:+ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.2347e-020.2181image
ENSG00000167562.10,ZNF701ESCAGSVA_HALLMARK_MYOGENESISEAG1.9207e-050.3527image
ENSG00000167562.10,ZNF701HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.3687e-02-0.1506image
chr19:52556155-52558680:+KICHGSVA_HALLMARK_PEROXISOMEEER7.9440e-030.3396image
ENSG00000167562.10,ZNF701KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG6.9340e-100.3148image
chr19:52559752-52560325:+KIRCGSVA_HALLMARK_DNA_REPAIREER5.6397e-030.2791image
chr19:52556155-52558680:+KIRCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.4598e-020.1227image
chr19:52556155-52558680:+KIRPGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER7.7554e-03-0.2001image
ENSG00000167562.10,ZNF701KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.1698e-050.2480image
ENSG00000167562.10,ZNF701LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.3471e-030.2381image
chr19:52556155-52558680:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.2562e-020.2120image
ENSG00000167562.10,ZNF701LGGGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.2800e-03-0.1330image
chr19:52556155-52558680:+LIHCGSVA_HALLMARK_ADIPOGENESISEER9.5944e-040.4966image
ENSG00000167562.10,ZNF701LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.1609e-020.1931image
ENSG00000167562.10,ZNF701LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG8.4723e-040.1763image
chr19:52586253-52586565:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.5393e-040.2740image
chr19:52556155-52558680:+OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.1899e-030.2016image
ENSG00000167562.10,ZNF701OVGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.8862e-04-0.2225image
chr19:52556155-52558680:+PAADGSVA_HALLMARK_MYC_TARGETS_V1EER6.7890e-03-0.3022image
ENSG00000167562.10,ZNF701PCPGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG6.5589e-030.2078image
chr19:52556155-52558680:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.4737e-020.2299image
ENSG00000167562.10,ZNF701PRADGSVA_HALLMARK_ADIPOGENESISEAG4.1275e-040.1599image
chr19:52556155-52558680:+PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.5845e-030.2080image
ENSG00000167562.10,ZNF701READGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.0363e-02-0.2283image
chr19:52556155-52558680:+SARCGSVA_HALLMARK_GLYCOLYSISEER1.2138e-020.2440image
ENSG00000167562.10,ZNF701SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.9200e-030.2109image
ENSG00000167562.10,ZNF701SKCMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.4194e-030.1518image
chr19:52556155-52558680:+SKCMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2314e-030.2298image
chr19:52556155-52558680:+STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.8099e-030.1719image
ENSG00000167562.10,ZNF701STADGSVA_HALLMARK_HYPOXIAEAG1.8937e-080.3020image
chr19:52586253-52586565:+STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.5909e-020.1767image
chr19:52559752-52560325:+STADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5162e-03-0.1912image
chr19:52586253-52586565:+TGCTGSVA_HALLMARK_GLYCOLYSISEER1.1839e-03-0.3383image
chr19:52556155-52558680:+TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER1.3369e-02-0.2291image
ENSG00000167562.10,ZNF701TGCTGSVA_HALLMARK_MYC_TARGETS_V1EAG1.7836e-10-0.4839image
ENSG00000167562.10,ZNF701THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.2649e-060.2001image
chr19:52556155-52558680:+THCAGSVA_HALLMARK_ADIPOGENESISEER5.4646e-03-0.1345image
chr19:52556155-52558680:+THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.2705e-02-0.2629image
ENSG00000167562.10,ZNF701THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.5512e-04-0.3334image
ENSG00000167562.10,ZNF701UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.8460e-030.2352image
chr19:52556155-52558680:+UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8866e-020.2688image
ENSG00000167562.10,ZNF701UCSGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.2109e-020.3523image
ENSG00000167562.10,ZNF701UVMGSVA_HALLMARK_MYOGENESISEAG1.3780e-030.5130image


Top

7. Enriched editing regions and drugs for ZNF701


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000167562.10,ZNF701ACCJNK.Inhibitor.VIIIEAG1.4271e-020.3050image
ENSG00000167562.10,ZNF701BLCACMKEAG2.1654e-04-0.1996image
chr19:52556155-52558680:+BLCACytarabineEER3.6986e-020.1437image
chr19:52586253-52586565:+BRCAAICAREER1.1033e-03-0.1690image
chr19:52556155-52558680:+BRCAA.770041EER9.1089e-04-0.1173image
ENSG00000167562.10,ZNF701BRCABIRB.0796EAG2.6716e-040.1134image
ENSG00000167562.10,ZNF701CESCDasatinibEAG1.1501e-02-0.1667image
chr19:52556155-52558680:+CESCBMS.708163EER3.3722e-020.1777image
chr19:52556155-52558680:+CHOLEHT.1864EER6.1872e-040.6982image
chr19:52556155-52558680:+COADLFM.A13EER1.2143e-02-0.2551image
ENSG00000167562.10,ZNF701COADGSK.650394EAG2.7732e-020.1488image
ENSG00000167562.10,ZNF701DLBCMethotrexateEAG1.4304e-040.5850image
ENSG00000167562.10,ZNF701ESCAGNF.2EAG5.7628e-06-0.3727image
chr19:52556155-52558680:+ESCACGP.60474EER2.8542e-05-0.3569image
chr19:52556155-52558680:+GBMAxitinibEER3.9190e-020.2648image
ENSG00000167562.10,ZNF701GBMErlotinibEAG2.6835e-02-0.1927image
ENSG00000167562.10,ZNF701HNSCBryostatin.1EAG3.3843e-03-0.2068image
chr19:52556155-52558680:+KICHBicalutamideEER4.4335e-030.3624image
ENSG00000167562.10,ZNF701KICHA.443654EAG8.5230e-040.4067image
ENSG00000167562.10,ZNF701KIRCGNF.2EAG2.9016e-06-0.2414image
chr19:52559752-52560325:+KIRCCGP.082996EER5.8379e-03-0.2780image
chr19:52556155-52558680:+KIRCCyclopamineEER9.4117e-04-0.1913image
chr19:52556155-52558680:+KIRPGefitinibEER9.3318e-03-0.1955image
ENSG00000167562.10,ZNF701KIRPBX.795EAG1.6425e-03-0.1918image
ENSG00000167562.10,ZNF701LAMLBMS.509744EAG2.4062e-02-0.1842image
chr19:52556155-52558680:+LAMLGDC.0449EER1.4953e-020.2068image
ENSG00000167562.10,ZNF701LGGJW.7.52.1EAG1.7995e-030.1592image
ENSG00000167562.10,ZNF701LUADCytarabineEAG4.1441e-020.1003image
chr19:52556155-52558680:+LUADBIRB.0796EER1.0102e-02-0.1530image
ENSG00000167562.10,ZNF701LUSCBMS.708163EAG1.4720e-02-0.1294image
chr19:52556155-52558680:+OVGefitinibEER4.2471e-03-0.1961image
ENSG00000167562.10,ZNF701OVAZD6244EAG4.6026e-04-0.2091image
chr19:52586253-52586565:+OVCHIR.99021EER1.4425e-060.3559image
chr19:52556155-52558680:+PAADAZD6482EER2.5981e-03-0.3429image
chr19:52556155-52558680:+PCPGGefitinibEER1.6899e-020.2254image
chr19:52556155-52558680:+PRADLFM.A13EER3.0138e-030.1956image
ENSG00000167562.10,ZNF701PRADBMS.708163EAG1.5224e-03-0.1437image
ENSG00000167562.10,ZNF701READCyclopamineEAG1.8591e-02-0.2610image
chr19:52556155-52558680:+SARCAZD.2281EER9.9721e-05-0.3706image
ENSG00000167562.10,ZNF701SARCMetforminEAG2.8626e-030.2029image
ENSG00000167562.10,ZNF701SKCMBIBW2992EAG3.2484e-04-0.1994image
chr19:52556155-52558680:+SKCMAZD6482EER4.4690e-05-0.2879image
chr19:52556155-52558680:+STADBortezomibEER6.5273e-04-0.1957image
chr19:52559752-52560325:+STADBAY.61.3606EER4.3632e-040.2356image
ENSG00000167562.10,ZNF701STADBexaroteneEAG3.8651e-05-0.2235image
chr19:52586253-52586565:+STADEpothilone.BEER5.2637e-030.2203image
chr19:52586253-52586565:+TGCTIPA.3EER8.1627e-05-0.4053image
chr19:52556155-52558680:+TGCTKU.55933EER4.1163e-030.2645image
ENSG00000167562.10,ZNF701TGCTLFM.A13EAG5.7399e-14-0.5562image
chr19:52556155-52558680:+THCAMethotrexateEER1.6984e-04-0.1821image
ENSG00000167562.10,ZNF701THCABMS.708163EAG2.4824e-08-0.2456image
ENSG00000167562.10,ZNF701THYMBIBW2992EAG4.2888e-04-0.3217image
chr19:52556155-52558680:+THYMBI.2536EER6.3163e-03-0.3126image
ENSG00000167562.10,ZNF701UCECLFM.A13EAG1.1447e-03-0.2556image
chr19:52556155-52558680:+UCECAxitinibEER5.6112e-030.3148image
ENSG00000167562.10,ZNF701UCSKIN001.135EAG2.0969e-03-0.4250image
ENSG00000167562.10,ZNF701UVMMethotrexateEAG6.4975e-030.4453image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType